Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer

di Patel, Jesal C., Maughan, Benjamin L., Agarwal, Archana M., Batten, Julia A., Zhang, Tian Y., Agarwal, Neeraj
Pubblicazione 2013

Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration resistant prostate cancer treated with abiraterone without prednisone

di Gill, David, Gaston, David, Bailey, Erin, Hahn, Andrew, Gupta, Sumati, Batten, Julia, Alex, Anitha, Boucher, Kenneth, Stenehjem, David, Agarwal, Neeraj
Pubblicato in Clin Genitourin Cancer (2017)

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical...

di Maughan, Benjamin L., Pal, Sumanta K., Gill, David, Boucher, Kenneth, Martin, Christopher, Salgia, Meghan, Nussenzveig, Roberto, Liu, Ting, Hawks, Josiah L., Batten, Julia, Nachaegari, Gayatri, Stephenson, Robert, Lowrance, William, Jones, Jeremy, Dechet, Christopher, Agarwal, Neeraj
Pubblicato in Oncologist (2018)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

di Cheng, Heather H., Gulati, Roman, Azad, Arun, Nadal, Rosa, Twardowski, Przemyslaw, Vaishampayan, Ulka N., Agarwal, Neeraj, Heath, Elisabeth I., Pal, Sumanta K., Rehman, Hibba-tul, Leiter, Amanda, Batten, Julia A., Montgomery, R. Bruce, Galsky, Matthew D., Antonarakis, Emmanuel S., Chi, Kim N., Yu, Evan Y.
Pubblicato in Prostate Cancer Prostatic Dis (2015)